Stock 600993 MAYINGLONG PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mayinglong Pharmaceutical Group Co., LTD.

Equities

600993

CNE000001HN2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-07-01 EDT 		5-day change 1st Jan Change
26.55 CNY -2.50% Intraday chart for Mayinglong Pharmaceutical Group Co., LTD. -0.56% +9.80%
04-19 Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-17 Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment MT

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 10,423 11,444 - -
Enterprise Value (EV) 1 10,423 11,444 11,444 11,444
P/E ratio - - - -
Yield - - - -
Capitalization / Revenue 3.32 x 3.18 x 2.81 x 2.51 x
EV / Revenue 3.32 x 3.18 x 2.81 x 2.51 x
EV / EBITDA - 18.3 x 15.8 x 13.2 x
EV / FCF - 32.7 x 32.3 x 18.2 x
FCF Yield - 3.06% 3.09% 5.49%
Price to Book - 2.78 x 2.51 x 2.25 x
Nbr of stocks (in thousands) 431,054 431,054 - -
Reference price 2 24.18 26.55 26.55 26.55
Announcement Date 4/12/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025 2026
Net sales 1 3,137 3,600 4,067 4,559
EBITDA 1 - 626 723 865
EBIT 1 - 657 747 899
Operating Margin - 18.25% 18.37% 19.72%
Earnings before Tax (EBT) - - - -
Net income 443.3 - - -
Net margin 14.13% - - -
EPS - - - -
Free Cash Flow 1 - 350.5 353.8 628.8
FCF margin - 9.74% 8.7% 13.79%
FCF Conversion (EBITDA) - 55.99% 48.94% 72.7%
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 4/12/24 - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025 2026
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - 350 354 629
ROE (net income / shareholders' equity) - 13.4% 13.8% 14.8%
ROA (Net income/ Total Assets) - 10.7% 11.1% 12%
Assets - - - -
Book Value Per Share 2 - 9.560 10.60 11.80
Cash Flow per Share - - - -
Capex 1 - 71 176 80.6
Capex / Sales - 1.97% 4.32% 1.77%
Announcement Date 4/12/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
26.55 CNY
Average target price
35 CNY
Spread / Average Target
+31.83%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. Stock Mayinglong Pharmaceutical Group Co., LTD.
+9.80% 1.61B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.27% 43.7B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+29.38% 23.11B
SANDOZ GROUP AG Stock Sandoz Group AG
+20.07% 15.43B
CIPLA LIMITED Stock Cipla Limited
+20.11% 14.31B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+60.14% 12.87B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.92% 6.45B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+13.00% 5.55B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600993 Stock
  4. Financials Mayinglong Pharmaceutical Group Co., LTD.